TORONTO, Oct. 14, 2016 /CNW/ - PharmaCielo Ltd. is pleased to announce that Dr. Pritesh Kumar has accepted appointment to the position of Chief Scientific Officer for the company, effective immediately. Dr. Kumar is a research scientist with a specialization in cannabinoid pharmacology and will be responsible for leading PharmaCielo’s research activities and partnerships globally.
“As one of the world’s leading experts in cannabinoid pharmacology research, Dr. Kumar brings unique skills and experience to the PharmaCielo team that will help drive our global business strategy,” said Dr. Patricio Stocker, President and CEO of PharmaCielo Ltd. “As a published scientist, Dr. Kumar’s experience in the establishment of research and laboratory protocols as well as working with the global scientific community will be valuable in ensuring the ability of our operations to achieve the highest global standards of product quality and efficacy.”
Dr. Kumar earned his PhD in Pharmacology and Toxicology with a focus in cannabinoid pharmacology from the University of Louisville. He is a cannabinoid research scientist, pharmacologist, laboratory manager and consultant trained in ensuring QA/QC, cGMP, GPP and cGLP of pharmaceutical products and Active Pharmaceutical Ingredients (APIs).
“I am looking forward to this opportunity to become part of the PharmaCielo team and to develop the scientific infrastructure necessary to achieve the highest quality and efficacy objectives in the production of cannabis oil extracts,” said Dr. Kumar. “After many years in the field providing consulting services to researchers, regulators and entrepreneurs alike about the scientific requirements of producing consistent and pure medicinal cannabinoid-based therapeutics, I know that the quality standards identified by PharmaCielo are among the highest in the world.”
Separately, Dr. Kumar will continue in his complementary role as CEO of PhytoSciences where he leads a team of 40+ global scientists and physicians primarily focused on developing safe, consistent and pure medicinal cannabinoid-based therapeutics and consulting on R&D, manufacturing, bioprocessing, clinical trial solutions and laboratory development pertaining to cannabinoid-based therapeutics.
Dr. Kumar has been published in numerous scientific journals including the European Journal of Pharmacology, Pharmacology and Physiology, Journal of Medicinal Chemistry, Investigative Ophthalmology & Visual Science and Biochemical and Biophysical Research Communications and authored a book chapter on polymorphisms in the CB2 and related impacts to certain pathologies. He is an active member of the International Cannabinoid Research Society (ICRS) and a former member of the American Society of Cell Biology (ASCB), National Glaucoma Society (NGS), Liaison Committee on Medical Education (LCME) of the University Of Louisville School Of Medicine and the University of Louisville’s Technology Subcommittee.
In a separate initiative, Dr. Kumar announced PharmaCielo’s establishment of a Research Advisory Board and the appointment of a series of eminent research scientists to the board.
About PharmaCielo Ltd:
PharmaCielo Ltd. (the “Company”) is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. The Company’s principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product rollout, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
SOURCE PharmaCielo
